Screener
Artiva Biotherapeutics, Inc. ARTV Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| Line item | SIX MONTHS ENDED JUNE 30, 2026 | SIX MONTHS ENDED JUNE 30, 2025 |
|---|---|---|
| Purchases of property and equipment | (657) | (1,566) |
| Purchases of investments | (6,442) | (24,591) |
| Maturities of investments | 40,000 | 57,250 |
| Net cash provided by investing activities | 32,901 | 31,093 |
| Financing activities: | ||
| Proceeds from public offering of common stock and issuance of pre-funded warrants | 300,000 | — |
| Issuance costs paid in connection with public offering of common stock and issuance of pre-funded warrants | (16,793) | — |
| Proceeds from exercise of stock options | 67 | 138 |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s investing cash flow?
- Artiva Biotherapeutics, Inc. (ARTV) reported investing cash flow of $17.59M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s investing cash flow changed year-over-year?
- Artiva Biotherapeutics, Inc.'s investing cash flow decreased by 16.7% year-over-year, from $21.12M to $17.59M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Artiva Biotherapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude